治疗重症低血压新药——血管紧张素Ⅱ
|
摘要
休克是组织灌流不足引起的代谢和细胞受损的病理过程,与低血压相关。血管紧张素Ⅱ(AngiotensinⅡ,AngⅡ)是一种有效的血管升压药,可以升高成人脓毒性或其他分布性休克患者的血压。本文从AngⅡ的作用机制和药物结构、药动学、临床研究、用法用量、药物相互作用、药物安全性及不良反应等方面进行综述。
Shock is a pathological process of metabolism and cellular damage caused by inadequate perfusion of tissue,which is always associated with hypotension. AngiotensinⅡ is a potent vasopressor,which can increase blood pressure in patients with sepsis or other septic shock in adults. This article reviewsits mechanism of action and drug structure,pharmacokinetics,clinical research,usage and dosage,drug interactions,drug safety and adverse reactions,etc.
Shock is a pathological process of metabolism and cellular damage caused by inadequate perfusion of tissue,which is always associated with hypotension. AngiotensinⅡ is a potent vasopressor,which can increase blood pressure in patients with sepsis or other septic shock in adults. This article reviewsits mechanism of action and drug structure,pharmacokinetics,clinical research,usage and dosage,drug interactions,drug safety and adverse reactions,etc.
引文
[1]Singer M,Deutschman CS,Seymour CW,et al.The third international consensus definitions for sepsis and septic shock(Sepsis-3)[J].JAMA,2016,315(8):801-810.
[2]Martin GS.Sepsis,severe sepsis and septic shock:changes in incidence,pathogens and outcomes[J].Expert Rev Anti Infect Ther,2012,10(6):701-706.
[3]Cohen J,Vincent JL,Adhikari NK,et al.Sepsis:a roadmap for future research[J].Lancet Infect Dis,2015,15(5):581-614.
[4]Rhodes A,Evans LE,Alhazzani W,et al.Surviving sepsis campaign:international guidelines for management of sepsis and septic shock:2016[J].Intensive Care M ed,2017,43(3):304-377.
[5]Karnik SS,Unal H,Kemp JR,et al.International union of basic and Clinical Pharmacology.XCIX.Angiotensin receptors:interpreters of pathophysiological angiotensinergic stimuli[J].Pharmacol Rev,2015,67(4):754-819.
[6]Basso N,Terragno NA.History about the discovery of the reninangiotensin system[J].Hypertension,2001,38(6):1246-1249.
[7]Busse LW,McCurdy MT,Ali O,et al.The effect of angiotensin IIon blood pressure in patients with circulatory shock:a structured review of the literature[J].Crit Care,2017,21(1):324.
[8]Donato L,Coli A,Pasqualini R,et al.Metabolic clearance rate of radioiodinated angiotensin II in normal men[J].Am JPhysiol,1972,223(5):1250-1256.
[9]Magness RR,Cox K,Rosenfeld CR,et al.Angiotensin II metabolic clearance rate and pressor responses in nonpregnant and pregnant w omen[J].Am J Obstet Gynecol,1994,171(3):668-679.
[10]Corrêa TD,Jeger V,Pereira AJ,et al.Angiotensin II in septic shock:effects on tissue perfusion,organ function,and mitochondrial respiration in a porcine model of fecal peritonitis[J].Crit Care Med,2014,42(8):e550-e559.
[11]Chawla LS,Russell JA,Bagshaw SM,et al.Angiotensin II for the treatment of High-Output Shock 3(ATHOS-3):protocol for a phase III,double-blind,randomised controlled trial[J].Crit Care Resusc,2017,19(1):43-49.
[12]Vittorio TJ,Lang CC,Katz SD,et al.Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockers[J].Circulation,2003,107(2):290-293.
[13]Ferrario CM,Trask AJ,Jessup JA.Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7)in regulation of cardiovascular function[J].Am J Physiol Heart Circ Physiol,2005,289(6):H2281-H2290.
[14]Chawla LS,Busse L,Brasha-Mitchell E,et al.Intravenous angiotensin II for the treatment of high-output shock(ATHOStrial):a pilot study[J].Crit Care,2014,18(5):534.
[15]Ames RP,Borkowski AJ,Sicinski AM,et al.Prolonged infusions of angiotensin ii and norepinephrine and blood pressure,electrolyte balance,and aldosterone and cortisol secretion in normal man and in cirrhosis w ith ascites[J].J Clin Invest,1965,44:1171-1186.
[16]Fernández-Ruiz I.Pharmacotherapy:angiotensin II-a new tool in vasodilatory shock[J].Nat Rev Cardiol,2017,14(7):384.
[17]Khanna A,English SW,Wang XS,et al.Angiotensin II for the treatment of vasodilatory shock[J].N Engl J M ed,2017,377(5):419-430.
[18]Dellinger RP,Trzeciak S.Angiotensin II for the treatment of vasodilatory shock-promise and caution[J].N Engl J M ed,2017,377(5):486-487.
[19]Kimmoun A,Levy B.Angiotensin II:a new approach for refractory shock management[J].Crit Care,2014,18(6):694.
[20]Chawla LS,Busse LW,Brasha-Mitchell E,et al.The use of angiotensin II in distributive shock[J].Crit Care,2016,20(1):137.
[21]Corrêa TD,Takala J,Jakob SM.Angiotensin II in septic shock[J].Crit Care,2015,19:98.
[22]Antonucci E,Gleeson PJ,Annoni F,et al.Angiotensin II in refractory septic shock[J].Shock,2017,47(5):560-566.
[23]Sato H,Sato K,Sato Y,et al.Induced hypertension chemotherapy of cancer patients by selective enhancement of drug delivery to tumor tissue w ith angiotensin II[J].Sci Rep Res Inst Tohoku Univ M ed,1981,28(1-4):32-44.
[2]Martin GS.Sepsis,severe sepsis and septic shock:changes in incidence,pathogens and outcomes[J].Expert Rev Anti Infect Ther,2012,10(6):701-706.
[3]Cohen J,Vincent JL,Adhikari NK,et al.Sepsis:a roadmap for future research[J].Lancet Infect Dis,2015,15(5):581-614.
[4]Rhodes A,Evans LE,Alhazzani W,et al.Surviving sepsis campaign:international guidelines for management of sepsis and septic shock:2016[J].Intensive Care M ed,2017,43(3):304-377.
[5]Karnik SS,Unal H,Kemp JR,et al.International union of basic and Clinical Pharmacology.XCIX.Angiotensin receptors:interpreters of pathophysiological angiotensinergic stimuli[J].Pharmacol Rev,2015,67(4):754-819.
[6]Basso N,Terragno NA.History about the discovery of the reninangiotensin system[J].Hypertension,2001,38(6):1246-1249.
[7]Busse LW,McCurdy MT,Ali O,et al.The effect of angiotensin IIon blood pressure in patients with circulatory shock:a structured review of the literature[J].Crit Care,2017,21(1):324.
[8]Donato L,Coli A,Pasqualini R,et al.Metabolic clearance rate of radioiodinated angiotensin II in normal men[J].Am JPhysiol,1972,223(5):1250-1256.
[9]Magness RR,Cox K,Rosenfeld CR,et al.Angiotensin II metabolic clearance rate and pressor responses in nonpregnant and pregnant w omen[J].Am J Obstet Gynecol,1994,171(3):668-679.
[10]Corrêa TD,Jeger V,Pereira AJ,et al.Angiotensin II in septic shock:effects on tissue perfusion,organ function,and mitochondrial respiration in a porcine model of fecal peritonitis[J].Crit Care Med,2014,42(8):e550-e559.
[11]Chawla LS,Russell JA,Bagshaw SM,et al.Angiotensin II for the treatment of High-Output Shock 3(ATHOS-3):protocol for a phase III,double-blind,randomised controlled trial[J].Crit Care Resusc,2017,19(1):43-49.
[12]Vittorio TJ,Lang CC,Katz SD,et al.Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockers[J].Circulation,2003,107(2):290-293.
[13]Ferrario CM,Trask AJ,Jessup JA.Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7)in regulation of cardiovascular function[J].Am J Physiol Heart Circ Physiol,2005,289(6):H2281-H2290.
[14]Chawla LS,Busse L,Brasha-Mitchell E,et al.Intravenous angiotensin II for the treatment of high-output shock(ATHOStrial):a pilot study[J].Crit Care,2014,18(5):534.
[15]Ames RP,Borkowski AJ,Sicinski AM,et al.Prolonged infusions of angiotensin ii and norepinephrine and blood pressure,electrolyte balance,and aldosterone and cortisol secretion in normal man and in cirrhosis w ith ascites[J].J Clin Invest,1965,44:1171-1186.
[16]Fernández-Ruiz I.Pharmacotherapy:angiotensin II-a new tool in vasodilatory shock[J].Nat Rev Cardiol,2017,14(7):384.
[17]Khanna A,English SW,Wang XS,et al.Angiotensin II for the treatment of vasodilatory shock[J].N Engl J M ed,2017,377(5):419-430.
[18]Dellinger RP,Trzeciak S.Angiotensin II for the treatment of vasodilatory shock-promise and caution[J].N Engl J M ed,2017,377(5):486-487.
[19]Kimmoun A,Levy B.Angiotensin II:a new approach for refractory shock management[J].Crit Care,2014,18(6):694.
[20]Chawla LS,Busse LW,Brasha-Mitchell E,et al.The use of angiotensin II in distributive shock[J].Crit Care,2016,20(1):137.
[21]Corrêa TD,Takala J,Jakob SM.Angiotensin II in septic shock[J].Crit Care,2015,19:98.
[22]Antonucci E,Gleeson PJ,Annoni F,et al.Angiotensin II in refractory septic shock[J].Shock,2017,47(5):560-566.
[23]Sato H,Sato K,Sato Y,et al.Induced hypertension chemotherapy of cancer patients by selective enhancement of drug delivery to tumor tissue w ith angiotensin II[J].Sci Rep Res Inst Tohoku Univ M ed,1981,28(1-4):32-44.